Search results for "Clinical science"

showing 10 items of 105 documents

Associations of ofatumumab exposure and treatment outcomes in patients with untreated CLL receiving chemoimmunotherapy

2016

Relationships between patient characteristics, ofatumumab pharmacokinetics, and treatment outcomes were investigated in this phase 2 trial of ofatumumab plus fludarabine and cyclophosphamide (FC) in untreated chronic lymphocytic leukemia. Patients were randomized 1:1 to receive 500 or 1000 mg ofatumumab (Cycle 1; 300 mg) plus FC every 4 weeks for six cycles. Median C(max) and C(trough) values were similar at Cycle 1 regardless of the ultimate clinical outcome. At later doses, these values were higher for patients with complete response (CR) than for other patients. Higher C(max) and C(trough) values at Cycles 3 and 6 were significantly associated with an increased likelihood of CR, whereas …

OncologyMaleCancer ResearchLymphomaDrug ResistanceMedizinKaplan-Meier EstimatePharmacologychemistry.chemical_compound0302 clinical medicineAntineoplastic Agents ImmunologicalRecurrencehemic and lymphatic diseasesAntineoplastic Combined Chemotherapy Protocols80 and overChronicNeoplasm MetastasisLenalidomideCancerAged 80 and overUnivariate analysisLeukemiaRemission InductionAntibodies MonoclonalHematologyphase IIMiddle AgedLymphocyticThalidomideFludarabineClinical trialTreatment OutcomeOncologyTolerability6.1 Pharmaceuticals030220 oncology & carcinogenesisRetreatmentMathematikRituximabFemalePatient SafetyRefractory Chronic Lymphocytic LeukemiaUntreated Chronic Lymphocytic Leukemiamedicine.drugAdultmedicine.medical_specialtyCyclophosphamidelenalidomideClinical Trials and Supportive ActivitiesClinical SciencesImmunologyCmaxAntineoplastic AgentsNeutropeniaOfatumumabAntibodies Monoclonal HumanizedDrug Administration ScheduleArticle03 medical and health sciencesRare DiseasesClinical ResearchChemoimmunotherapyInternal medicinemedicineImmunologic FactorsAnimalsHumansIn patientAdverse effectLenalidomideAgedNeoplasm StagingChromosome Aberrationsbusiness.industryB-CellEvaluation of treatments and therapeutic interventionsmedicine.diseaseHaresLeukemia Lymphocytic Chronic B-CellDiscontinuationClinical trialchemistryDrug Resistance NeoplasmNeoplasmbusinessCLL030215 immunology
researchProduct

Phase III Trial of Avelumab Maintenance After First-Line Induction Chemotherapy Versus Continuation of Chemotherapy in Patients With Gastric Cancers:…

2021

PURPOSE The role of maintenance therapy for gastric (GC) or gastroesophageal junction cancer (GEJC) is unclear. We investigated avelumab (anti–programmed death ligand-1 [PD-L1]) maintenance after first-line induction chemotherapy for GC/GEJC. PATIENTS AND METHODS JAVELIN Gastric 100 was a global, open-label, phase III trial. Eligible patients had untreated, unresectable, human epidermal growth factor receptor 2–negative, locally advanced or metastatic GC or GEJC. Patients without progressive disease after 12 weeks of first-line chemotherapy with oxaliplatin plus a fluoropyrimidine were randomly assigned 1:1 to avelumab 10 mg/kg every 2 weeks or continued chemotherapy, stratified by region (…

OncologyMaleCancer Researchmedicine.medical_treatmentAvelumab0302 clinical medicineMaintenance therapyMonoclonalAntineoplastic Combined Chemotherapy Protocols030212 general & internal medicineMulticenterHumanizedCancerbiologyInduction ChemotherapyMiddle AgedPrognosisOxaliplatinSurvival RateOncology6.1 Pharmaceuticals030220 oncology & carcinogenesisFemaleFluorouracilmedicine.drugDouble-Blindmedicine.medical_specialtyFirst lineClinical Trials and Supportive ActivitiesClinical SciencesOncology and CarcinogenesisAntibodies Monoclonal HumanizedAntibodiesMaintenance Chemotherapy03 medical and health sciencesRare DiseasesClinical ResearchJavelinStomach NeoplasmsInternal medicinemedicineHumansIn patientOncology & CarcinogenesisCapecitabineAgedChemotherapybusiness.industryEvaluation of treatments and therapeutic interventionsInduction chemotherapyCancerbiology.organism_classificationmedicine.diseaseOpen-LabelTherapyCisplatinbusinessFollow-Up StudiesJournal of clinical oncology : official journal of the American Society of Clinical Oncology
researchProduct

Familial hypercholesterolaemia: A global call to arms

2015

Familial Hypercholesterolaemia (FH) is the commonest autosomal co-dominantly inherited condition affecting man. It is caused by mutation in one of three genes, encoding the low-density lipoprotein (LDL) receptor, or the gene for apolipoprotein B (which is the major protein component of the LDL particle), or in the gene coding for PCSK9 (which is involved in the degradation of the LDL-receptor during its cellular recycling). These mutations result in impaired LDL metabolism, leading to life-long elevations in LDL-cholesterol (LDL-C) and development of premature atherosclerotic cardiovascular disease (ASCVD) [1], [2] and [3]. If left untreated, the relative risk of premature coronary artery d…

PathologyApolipoprotein BDisease030204 cardiovascular system & hematologymedicine.disease_causeGlobal HealthDISEASEDoenças Cardio e Cérebro-vasculares0302 clinical medicineHyperlipoproteinemia Type IISocieties MedicalRISK0303 health sciencesMutationbiology3. Good healthPREVALENCEEuropelipids (amino acids peptides and proteins)Cardiology and Cardiovascular MedicineFamilial hypercholesterolaemiaLife Sciences & Biomedicinemedicine.medical_specialtyHeterozygote1102 Cardiovascular Medicine And HaematologyHyperlipoproteinemia Type II03 medical and health sciencesInternal medicinemedicineHumans030304 developmental biologyScience & Technologybusiness.industryGUIDANCEPCSK9Heterozygote advantage1103 Clinical SciencesEndocrinologyPeripheral Vascular DiseaseCardiovascular System & HematologyReceptors LDLRECEPTORES DE LIPOPROTEÍNASRelative riskMutationbiology.proteinCardiovascular System & CardiologyFamilial HypercholesterolaemiabusinessCLINICIANLipoprotein
researchProduct

Depressive Symptom Profiles Predict Specific Neurodegenerative Disease Syndromes in Early Stages

2020

Background: During early stages, patients with neurodegenerative diseases (NDG) often present with depressive symptoms. However, because depression is a heterogeneous disorder, more precise delineation of the specific depressive symptom profiles that arise early in distinct NDG syndromes is necessary to enhance patient diagnosis and care. Methods and Findings: Five-hundred and sixty four participants self-reported their depressive symptoms using the Geriatric Depression Scale (GDS), including 111 healthy older control subjects (NC) and 453 patients diagnosed with one of six NDGs who were at the mild stage of disease (CDR® Dementia Staging Instrument ≤ 1) [186 Alzheimer's disease (AD), 76 be…

PediatricsAgingDiseaseNeurodegenerativeAlzheimer's Diseasefrontotemporal dementialcsh:RC346-429Primary progressive aphasia0302 clinical medicineneurodegenerative diseasehopelessnessworry2.1 Biological and endogenous factorsPsychology030212 general & internal medicineAetiologyDepression (differential diagnoses)Original ResearchdysphoraDepressionAlzheimer'sFrontotemporal Dementia (FTD)Mental HealthNeurologyNeurologicaldepressionGeriatric Depression Scalemedicine.symptomFrontotemporal dementiamedicine.medical_specialtyClinical SciencesDysphoriaProgressive supranuclear palsy7.3 Management and decision making03 medical and health sciencesRare DiseasesClinical ResearchBehavioral and Social SciencemedicineAcquired Cognitive ImpairmentDementialcsh:Neurology. Diseases of the nervous systembusiness.industryNeurosciencesAlzheimer's Disease including Alzheimer's Disease Related Dementias (AD/ADRD)progressive supranuclear palsymedicine.diseaseBrain DisordersGood Health and Well BeingDementiaNeurology (clinical)Management of diseases and conditionsbusiness030217 neurology & neurosurgeryFrontiers in Neurology
researchProduct

Expertise

2017

Several sets of guidelines have been published recently and more are in the works. The very recent American College of Physicians/American Academy of Family Practitioners guidelines were put together by a set of authors and consultants without any expertise in the topic under discussion, that is, hypertension. Although we are not maintaining that all guidelines should be written exclusively by experts, complete lack of expertise among guideline authors is not acceptable. ispartof: Journal Of Hypertension vol:35 issue:8 pages:1564-1566 ispartof: location:Netherlands status: published

Pediatricsmedicine.medical_specialtyhypertensionPhysiologySine qua nonAlternative medicineMEDLINE030204 cardiovascular system & hematology1102 Cardiovascular Medicine And Haematology03 medical and health sciencesProfessional Competence0302 clinical medicineInternal MedicinemedicineHumansBLOOD-PRESSURE TARGETSguidelines030212 general & internal medicineSet (psychology)Societies MedicalMETAANALYSISANGIO-EDEMAOLDERMedical educationScience & Technologybusiness.industry1103 Clinical SciencesAGED 60 YEARSGuidelineProfessional competence3. Good healthPeripheral Vascular DiseaseCardiovascular System & HematologyPractice Guidelines as TopicCardiovascular System & CardiologyexpertiseINHIBITORSCardiology and Cardiovascular MedicinebusinessLife Sciences & BiomedicineguidelineANGIO-EDEMAJournal of Hypertension
researchProduct

Validation and utility of ARDS subphenotypes identified by machine-learning models using clinical data: an observational, multicohort, retrospective …

2022

Item does not contain fulltext BACKGROUND: Two acute respiratory distress syndrome (ARDS) subphenotypes (hyperinflammatory and hypoinflammatory) with distinct clinical and biological features and differential treatment responses have been identified using latent class analysis (LCA) in seven individual cohorts. To facilitate bedside identification of subphenotypes, clinical classifier models using readily available clinical variables have been described in four randomised controlled trials. We aimed to assess the performance of these models in observational cohorts of ARDS. METHODS: In this observational, multicohort, retrospective study, we validated two machine-learning clinical classifie…

Pulmonary and Respiratory MedicineClinical SciencesAcute Lung InjuryArticleMachine LearningPositive-Pressure RespirationRare DiseasesClinical ResearchRetrospective StudieSettore MED/41 - ANESTESIOLOGIAHumansLungAcute Respiratory Distress SyndromeRetrospective StudiesRespiratory Distress SyndromeOther Medical and Health SciencesLUNG SAFE Investigators and the ESICM Trials Grouplnfectious Diseases and Global Health Radboud Institute for Health Sciences [Radboudumc 4]PhenotypeGood Health and Well BeingArea Under CurveARDS: PhenotypeRespiratoryPublic Health and Health ServicesARDSHuman
researchProduct

Protocol for the EARCO Registry

2020

Rationale and objectives Alpha-1 antitrypsin deficiency (AATD) is a genetic condition that leads to an increased risk of emphysema and liver disease. Despite extensive investigation, there remain unanswered questions concerning the natural history, pathophysiology, genetics and the prognosis of the lung disease in association with AATD. The European Alpha-1 Clinical Research Collaboration (EARCO) is designed to bring together researchers from European countries and to create a standardised database for the follow-up of patients with AATD. Study design and population The EARCO Registry is a non-interventional, multicentre, pan-European, longitudinal observational cohort study enrolling patie…

Pulmonary and Respiratory Medicinemedicine.medical_specialtyChronic Obstructive Pulmonary DiseasePopulation1MEDLINElcsh:Medicine61032 Biomedical and Clinical Sciences610 Medicine & health[SDV.MHEP.PSR]Life Sciences [q-bio]/Human health and pathology/Pulmonology and respiratory tract03 medical and health sciencesLiver diseaseStudy Protocol0302 clinical medicineRare DiseasesClinical ResearchmedicineGenetics030212 general & internal medicineIntensive care medicineeducation3202 Clinical SciencesLungProtocol (science)Emphysemaeducation.field_of_studybusiness.industryPreventionlcsh:Rmedicine.disease3. Good healthNatural historyClinical research030228 respiratory systemObservational study10178 Clinic for PneumologybusinessCohort study
researchProduct

The Differences in the Prevalence of Cardiovascular Disease, Its Risk Factors, and Achievement of Therapeutic Goals among Urban and Rural Primary Car…

2021

A nationwide cross-sectional study, LIPIDOGRAM2015, was carried out in Poland in the years 2015 and 2016. A total of 438 primary care physicians enrolled 13,724 adult patients that sought medical care in primary health care practices. The prevalence of hypertension, diabetes mellitus, dyslipidaemia, and CVD were similar in urban and rural areas (49.5 vs. 49.4%; 13.7 vs. 13.1%; 84.2 vs. 85.2%; 14.4 vs. 14.2%, respectively). The prevalence of obesity (32.3 vs. 37.5%, p p p p = 0.04) and non-HDL-C (147 vs. 148 mg/dL, p = 0.03) were slightly higher in rural populations. Altogether, 14.3% of patients with CVD from urban areas and 11.3% from rural areas reached LDL p = 0.04). There were no import…

RMWaistDiseasePrimary careArticleDiabetes mellitusmedicinerisk factorsUrbanRuralAbdominal obesityPrimary health carebusiness.industryRprimary health care; cardiovascular diseases; risk factors; urban; rural; Poland1103 Clinical SciencesGeneral Medicinemedicine.diseaseObesitycardiovascular diseasesprimary health careCardiovascular diseasesBlood pressureRisk factorsMedicineruralPolandRural areamedicine.symptombusinessurbanDemography
researchProduct

AGuIX® from bench to bedside-Transfer of an ultrasmall theranostic gadolinium-based nanoparticle to clinical medicine.

2019

International audience; AGuIX® are sub-5 nm nanoparticles made of a polysiloxane matrix and gadolinium chelates. This nanoparticle has been recently accepted in clinical trials in association with radiotherapy. This review will summarize the principal preclinical results that have led to first in man administration. No evidence of toxicity has been observed during regulatory toxicity tests on two animal species (rodents and monkeys). Biodistributions on different animal models have shown passive uptake in tumours due to enhanced permeability and retention effect combined with renal elimination of the nanoparticles after intravenous administration. High radiosensitizing effect has been obser…

Radiation-Sensitizing AgentsGadoliniummedicine.medical_treatmentGadolinium02 engineering and technologyReview ArticlePharmacologyTheranostic NanomedicineMice0302 clinical medicineMelanomaBrain NeoplasmsMelanomaGeneral Medicine[CHIM.MATE]Chemical Sciences/Material chemistry[SDV.SP]Life Sciences [q-bio]/Pharmaceutical sciences021001 nanoscience & nanotechnology3. Good health[SDV.SP] Life Sciences [q-bio]/Pharmaceutical sciencesNuclear Medicine & Medical ImagingRadiology Nuclear Medicine and imagingHead and Neck Neoplasms030220 oncology & carcinogenesisToxicity/dk/atira/pure/sustainabledevelopmentgoals/good_health_and_well_being[SDV.IB]Life Sciences [q-bio]/Bioengineering0210 nano-technologyClinical Scienceschemistry.chemical_element[SDV.CAN]Life Sciences [q-bio]/CancerEnhanced permeability and retention effect03 medical and health sciences/dk/atira/pure/subjectarea/asjc/2700/2741SDG 3 - Good Health and Well-being[SDV.CAN] Life Sciences [q-bio]/CancerIn vivo[CHIM.ANAL]Chemical Sciences/Analytical chemistrymedicineAnimalsHumansRadiology Nuclear Medicine and imaging[SDV.IB] Life Sciences [q-bio]/Bioengineeringbusiness.industryCancermedicine.diseaseRadiation therapyClinical trialchemistryNanoparticlesbusinessForecasting
researchProduct

Global, regional, and national burden of diseases and injuries for adults 70 years and older:systematic analysis for the Global Burden of Disease 201…

2022

AbstractObjectivesTo use data from the Global Burden of Diseases, Injuries, and Risk Factors Study 2019 (GBD 2019) to estimate mortality and disability trends for the population aged ≥70 and evaluate patterns in causes of death, disability, and risk factors.DesignSystematic analysis.SettingParticipants were aged ≥70 from 204 countries and territories, 1990-2019.Main outcomes measuresYears of life lost, years lived with disability, disability adjusted life years, life expectancy at age 70 (LE-70), healthy life expectancy at age 70 (HALE-70), proportion of years in ill health at age 70 (PYIH-70), risk factors, and data coverage index were estimated based on standardised GBD methods.ResultsGlo…

RiskMale610 Medicine & healthCare1117 Public Health and Health ServicesGlobal Burden of DiseaseDisability EvaluationLife ExpectancyCost of IllnessDeclineRisk FactorsGeneral & Internal MedicineHumansObesityMortality610 Medicine & healthAgedAged 80 and overPublic Health Global Health Social Medicine and Epidemiology1103 Clinical SciencesGeneral MedicineMortality/trends3142 Public health care science environmental and occupational healthWounds and Injuries/epidemiologyFolkhälsovetenskap global hälsa socialmedicin och epidemiologiHealthWounds and InjuriesFemaleMorbidity
researchProduct